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Crossing Barriers; Restoring Barriers?
Filaggrin Protein Replacement
Takes a Bow
Alan D. Irvine1,2,3
In this issue of the Journal, Stout and colleagues report a novel and creative
approach to replacement of genetically determined absence or deficiency of
epidermal proteins. While these early data are certainly interesting, further validation
work is required to determine the utility of this approach in genodermatoses.
Journal of Investigative Dermatology (2014) 134, 313–314. doi:10.1038/jid.2013.506
One in ten Europeans carries at least one
filaggrin (FLG) loss-of-function (LOF)
mutation (Irvine and McLean, 2006).
These common variants are the stron-
gest genetic risk yet identified for atopic
dermatitis (AD), with an overall odds
ratio for AD of B4 (Rodriguez et al.,
2009). In addition to the risk of AD
posed by LOF mutations, variation in
FLG repeat numbers (10, 11, or 12
repeats; intragenic copy-number varia-
tion) also confers significant risk of
AD (Brown et al., 2012). Furthermore,
in addition to these genetically deter-
mined deficiencies in FLG produc-
tion, FLG expression is downregulated
secondarily in AD due to the disease
per se (Kezic et al., 2011), as recently
reviewed (McAleer and Irvine, 2013). In
addition to a role as an AD risk gene,
FLG LOFs are modifiers of disease
within AD. Individuals with AD who
carry a FLG LOF mutation are more
likely to develop asthma, to have more
severe and more persistent disease, to
have allergic sensitizations, and to
develop eczema herpeticum (McAleer
and Irvine, 2013).
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Filaggrin replacement therapies there-
fore have wide potential applicability in
management of AD. The FLG gene
encodes a proprotein that has no known
function when expressed in the granular
layer. Dephosphorylation of the propro-
tein, in concert with derepression of a
protease cascade, leads to rapid libera-
tion of functionally active filaggrin mono-
mers in an elaborately controlled process
(Sandilands et al., 2009). Theoretical
gene-based approaches to enhance or
replace FLG deficiency might include
read-through drugs that focus on the
mutant allele or drugs that increase FLG
expression by driving the promoter of
the ‘healthy’ allele or alleles. Direct
protein replacement is another potential
approach, but profilaggrin is an excep-
tionally large molecule, making replace-
ment difficult. Obstacles common to
all topical approaches to replacement
therapies are delivery across the stratum
corneum barrier and the need to target
the replacement gene or protein accura-
tely to the intracellular cytoplasmic space
in the relevant, differentiation-specific
epidermal compartments.
In this issue of the JID, Stout, et al.
(2014) report a novel and potentially
exciting approach to FLG replacement.
They have considered and attempted to
solve many of the obstacles mentioned
above. To reduce the size of the repla-
cement product, they produced, using a
commercially available bacterial expre-
ssion system, a single murine Flg repeat,
with flanking sequences to allow
processing. To achieve intracellular
delivery, they linked this repeat
sequence covalently to a cell-penetrating
peptide derived from the HIV TAT pro-
tein. They report a progressive series of
complementary experiments using cell
culture, skin equivalents, and the flaky
tail mouse. Their results show that the
recombinant protein is delivered, depen-
dent on the linked RMR motif, to the
keratinocyte cytoplasmic space. In human
skin equivalents and in the flaky tail
mouse, the protein is delivered through-
out the epidermis, as it is not restricted to
differentiation-specific compartments.
This lack of specificity may reflect the
importance of the full profilaggrin protein,
including the untranslated 50- and 30-
domains, in protein localization. Morpho-
logical aspects of the flaky tail stratum
corneum phenotype were apparently res-
tored. Analysis of post-translational
processing was restricted to proof of
production, presumably by proteolytic
cleavage of the protein construct, of a
single filaggrin repeat. The unintended
effects of FLG expression, including possi-
ble immunogenicity, in atypical epider-
mal compartments, including the basal
layer are unknown. Further analysis of the
complex post-translational modification
of FLG was not performed, and this will
be important to determine the likely
therapeutic effects of protein replacement.
An engineered peptide
with one filaggrin repeat
benefits skin in a mouse
model of AD.
These proof-of-principle results are
certainly interesting, but will require
further work, first to determine safety,
and then dosing and efficacy, including
dosing interval, and ultimately duration
of effect in human subjects. Although
the flaky tail mice do not appear to
mount an immunological response to
the fusion protein, humans may respond
differently. If such a therapy were to
overcome or avoid these issues and
become available for human use, it
might first be used in those with active
AD or problematic ichthyosis vulgaris. It
might also have a preventative role for
those who carry FLG-null alleles. To that
end, it will be important to identify
disease modifiers and predictors of dis-
ease in individuals with FLG mutations
because only 40% will develop AD.
Finally, this novel delivery system may
well have broader applicability for
patients with one of the many, now
genetically well understood, genoder-
matoses currently waiting for gene or
protein replacement therapies.
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Clinical Implications
 Loss-of-function (LOF) mutations in filaggrin (FLG) are common and
greatly increase the risk of developing atopic dermatitis.
 LOF FLG mutations also predispose to asthma, more severe and persistent
dermatitis, allergic sensitization, and eczema herpeticum, making protein
replacement an attractive treatment option.
 In the flaky mouse model, a targeted recombinant partial filaggrin protein,
applied topically, improves stratum corneum phenotype, suggesting
this may be a useful therapeutic approach. A caveat is that the
flaky tail mouse also harbors a mutation in TMEM79, which greatly
impairs barrier function and may facilitate easier transfer of the targeted
protein.
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